Intercept Pharmaceuticals, Inc. (ICPT)
Nov 8, 2023 - ICPT was delisted (reason: acquired by Alfasigma)
19.00
0.00 (0.00%)
Inactive · Last trade price on Nov 7, 2023
Intercept Pharmaceuticals Revenue
Intercept Pharmaceuticals had revenue of $88.79M in the quarter ending September 30, 2023, with 14.44% growth. This brings the company's revenue in the last twelve months to $317.68M, up 14.64% year-over-year. In the year 2022, Intercept Pharmaceuticals had annual revenue of $285.71M with 9.57% growth.
Revenue (ttm)
$317.68M
Revenue Growth
+14.64%
P/S Ratio
n/a
Revenue / Employee
$931,625
Employees
341
Market Cap
n/a
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2022 | 285.71M | 24.96M | 9.57% |
| Dec 31, 2021 | 260.75M | 26.78M | 11.45% |
| Dec 31, 2020 | 233.97M | -18.03M | -7.16% |
| Dec 31, 2019 | 252.00M | 72.20M | 40.15% |
| Dec 31, 2018 | 179.80M | 48.85M | 37.30% |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2013 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionICPT News
- 6 weeks ago - Intercept Pharma withdraws liver disease drug from US market - Reuters
- 11 months ago - US FDA says Intercept's drug can cause liver injury in patients without scarring - Reuters
- 1 year ago - US FDA declines full approval for Intercept's liver disease drug - Reuters
- 1 year ago - Intercept Receives Complete Response Letter from FDA Addressing OCALIVA supplemental New Drug Application (sNDA) - GlobeNewsWire
- 1 year ago - FDA advisers vote against confirmatory data for Intercept's liver disease drug - Reuters
- 1 year ago - FDA staff raises efficacy concerns over Intercept's liver disease drug - Reuters
- 1 year ago - Intercept Announces FDA Acceptance of Supplemental New Drug Application for Ocaliva® (obeticholic acid) for the Treatment of PBC - GlobeNewsWire
- 2 years ago - Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc. - GlobeNewsWire